Effect of the Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID-19 Pneumonia
A Prospective, Randomized, Comparative Study in Two Groups to Assess the Effect of the Use of a Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID Pneumonia and on the Biological Age
1 other identifier
interventional
100
1 country
1
Brief Summary
Objective of the study is to evaluate the effect of Taxifolin Aqua therapy on the indicators of respiratory function, the state of the arterial wall, the contractile function of the myocardium, as well as to assess the effect of Taxifolin Aqua therapy on markers of biological age, quality of patients life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable covid19
Started May 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 21, 2021
CompletedFirst Posted
Study publicly available on registry
May 4, 2021
CompletedStudy Start
First participant enrolled
May 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2021
CompletedMay 4, 2021
March 1, 2021
4 months
March 21, 2021
May 1, 2021
Conditions
Outcome Measures
Primary Outcomes (4)
Dynamics of spirometry indices
spirometry
In 2 months after recruitment
Dynamics of ECHO CG
ECHO CG
In 2 months after recruitment
Dynamics of pulse wave velocity
applanation tonometry
In 2 months after recruitment
Dynamics of augmentation index
applanation tonometry
In 2 months after recruitment
Secondary Outcomes (1)
Dynamics of biological age
In 2 months after recruitment
Study Arms (2)
Taxifolin Aqua group
EXPERIMENTALTaxifolin Aqua 30 mg per day in addition to standard therapy
Control group
NO INTERVENTIONNo intervention
Interventions
Eligibility Criteria
You may qualify if:
- Patients of both sexes who had covid pneumonia 3 months ago and signed an informed consent and aged 18+.
You may not qualify if:
- Standard contraindications to Taxifolin Aqua use.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Russian Clinical Research Center for Gerontology
Moscow, 129226, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Irina Strazhesko, MD, PhD
Clinical Reserach Center for Gerontology
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2021
First Posted
May 4, 2021
Study Start
May 10, 2021
Primary Completion
September 1, 2021
Study Completion
October 1, 2021
Last Updated
May 4, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will not share